Artificial Intelligence

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

A once-failed class of weight-loss drugs is back with a new design. Corbus Pharma's early data suggests it may have solved the safety puzzle.

Brii Biosciences partners with OpenBench, using an AI platform where they only pay for results. Is this the future of de-risking pharmaceutical R&D?

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

With $70M and a new CEO, Prolynx is leveraging a cancer-tested platform to create monthly obesity shots. Can it disrupt a billion-dollar market?

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

The U.S. Coast Guard taps AeroVironment for advanced underwater robots, a key step in its Force Design 2028 plan to boost safety and mission efficiency.

As agencies retool for a complex market, Bastion's appointment of a cultural PR expert highlights a critical shift for pharma and beyond.

Canadian grocer Empire posts strong sales but lower earnings. A deep dive into its dual strategy of store renewal and a major digital and data overhaul.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Dreame's 2025 holiday sale isn't just about vacuums; it's a strategic play to conquer the UK market with premium tech at aggressive prices.

With a new board chair and a clear shareholder mandate, Edgewater Wireless is shifting from R&D to monetizing its game-changing Spectrum Slicing tech.

Salesforce's AI agents are set to overhaul the USDOT, tackling legacy tech to speed up grants, enhance safety, and redefine federal efficiency.

As AI-driven fakes flood the world, a new asset class is born: authenticity. Discover how GME and Reality Defender are monetizing trust for government.

Fidelity and TIAA still lead, but strategic AI investments are fueling a surge from mid-tier players, redefining the competitive retirement landscape.

A single crypto campaign generates $53.5B in futures volume. We dissect MEXC's strategy and what it reveals about the exchange wars and token adoption.

Cincoze's new MD-3000 embeds desktop-grade AI power into a rugged box, promising zero-failure vision for resilient manufacturing operations.

Advantest's T2000 AiR2X isn't just new hardware. It's a calculated move to solve the chip industry's legacy pains and efficiency demands.